Interestingly, CCX721, a selective CCR1 inhibitor, improves osteolytic bone lesions in a preclinical mouse model of this disease.31 This compound is analogous to CCX354-C, an oral CCR1 antagonist that has been evaluated in clinical trial for human rheumatoid arthritis.32 Here, CCR1 is linked to rheumatoid arthritis.